Nektar Therapeutics (Alabama)
1112 Church Street
Huntsville
Alabama
35801
United States
Tel: 256-512-9200 or 877-451-6587
Fax: 256-704-7647
Website: http://www.nektar.com/
Email: nektarAL@nektar.com
About Nektar Therapeutics (Alabama)
Nektar Therapeutics has a robust R&D pipeline and portfolio of approved partnered medicines in oncology, pain, immunology and other therapeutic areas. In the area of oncology, Nektar is developing NKTR-214, an immuno-stimulatory CD122-biased agonist, which is in Phase 1/2 clinical development for patients with solid tumors. ONZEALD™ (etirinotecan pegol), a long-acting topoisomerase I inhibitor, is being developed for patients with advanced breast cancer and brain metastases and is partnered with Daiichi Sankyo in Europe. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™ (naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The product is also approved in the European Union as MOVENTIG® (naloxegol) and is indicated for adult patients with OIC who have had an inadequate response to laxatives. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly owned mu-opioid analgesic molecule for chronic pain conditions, is in Phase 3 development. In hemophilia, Nektar has a collaboration agreement with Baxalta for ADYNOVATE™ [Antihemophilic Factor (Recombinant)], a longer-acting PEGylated Factor VIII therapeutic approved in the U.S. andJapan for patients over 12 with hemophilia A. In anti-infectives, the company has two collaborations with Bayer Healthcare, Cipro Inhale in Phase 3 for non-cystic fibrosis bronchiectasis and Amikacin Inhale in Phase 3 for patients with Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK™, Baxalta's ADYNOVATE™, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.
Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.
86 articles about Nektar Therapeutics (Alabama)
-
Nektar Therapeutics (AL) Release: Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at American Association for Cancer Research Annual Meeting 2013
4/8/2013
-
Nektar Therapeutics (AL)'s NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
6/6/2011
-
Nektar Therapeutics (AL) Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 American Society of Clinical Oncology Annual Meeting
5/19/2011
-
FDA Grants Orphan Drug Designation For Nektar Therapeutics (AL)'s Investigational Drug (NKTR)
4/21/2011
-
Nektar Therapeutics (AL) Prices Public Offering of Common Stock
1/19/2011
-
Nektar Therapeutics Announces Two Preclinical Data Presentations at Society for Neuroscience 40th Annual Meeting: Neuroscience 2010
11/15/2010
-
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
11/5/2010
-
Nektar Therapeutics To Supply Polymer To Amgen, Nektar Will Receive $50 Million
11/2/2010
-
Nektar Therapeutics to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
10/29/2010
-
Nektar Therapeutics To Present at the UBS 2010 Global Life Sciences Conference
9/20/2010
-
Nektar Therapeutics Reports Second Quarter 2010 Financial Results
7/29/2010
-
Nektar Therapeutics to Announce Financial Results for the Second Quarter of 2010 On Wednesday, July 28, 2010, After Close of U.S.-Based Financial Markets
7/21/2010
-
Nektar Therapeutics' NKTR-102 Demonstrates Superior Activity to Irinotecan in Nonclinical Studies Presented at ESMO 12th World Congress on Gastrointestinal Cancer
7/6/2010
-
Nektar Therapeutics Announces Dosing of First Patients in Phase 1 Clinical Study of NKTR-102 in Combination With 5-Fluorouracil/Leucovorin
6/24/2010
-
Nektar Therapeutics Announces Positive Initial Results from Phase 2 Study of NKTR-102 in Metastatic Breast Cancer
6/9/2010
-
Nektar Therapeutics Ovarian Cancer Drug Benefits Women in Study
6/7/2010
-
Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies and Co. 2010 Global Life Sciences Healthcare Conference in New York
6/3/2010
-
Nektar Therapeutics: NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 American Society of Clinical Oncology Annual Meeting
5/21/2010
-
Nektar Therapeutics to Announce Financial Results for the First Quarter of 2010 on Wednesday, May 5, 2010, After Close of U.S.-Based Financial Markets
4/28/2010
-
Nektar Therapeutics (JOBS) Announces Positive Phase 2 Clinical Data from First Stage of NKTR-102 Study in Women with Platinum-Resistant Ovarian Cancer
3/8/2010